Compare GSK plc (GSK) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hut 8 Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Hut 8 Corp trades at $84.27 (market cap $9.82B). The key difference: GSK plc is far larger — about 9.4× Hut 8 Corp's market cap, and GSK plc pays a 3.9% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Hut 8 Corp for 11 Days on average.
| GSK | HUT | |
|---|---|---|
Market Cap | $91.88B | $9.82B |
Volume | 7,730,529 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $61.18 | $133.02 |
52-Week Low | $43.24 | $33.76 |
Typical Hold Time | 93 Days | 11 Days |
Enterprise Value | $111.88B | $17.25B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
HUT trades at $79.59, down 10.87% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -188.59% net income margin and has missed earnings expectations for three consecutive quarters. Recent positive developments include securing a $1.07 billion credit facility and growing institutional interest, positioning the company in the expanding AI infrastructure market.
While analyst consensus remains strongly bullish with a $162.69 price target, significant risks persist including ongoing losses, high valuation multiples, and competitive pressures in AI infrastructure. The stock's outlook hinges on successful execution of its business transformation and achieving profitability amid substantial capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
